Physician profile
James Jenkins
NPI 1023002177
$450.65
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $50.18 · 2021: $41.67 · 2022: $11.74 · 2023: $18.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.93 | 2019 | |
| Allergan, INC. | $60.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $54.60 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $26.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.85 | 2019 | |
| Amarin Pharma, INC. | $20.34 | 2019 | |
| Radius Health, INC. | $19.90 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.41 | 2019 | |
| Abbott Laboratories | $16.72 | 2021 | |
| Novo Nordisk INC | $14.48 | 2020 | |
| Genentech USA, INC. | $13.77 | 2019 | |
| Merck Sharp & Dohme LLC | $13.10 | 2019 | |
| Abbvie INC. | $11.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.